Clinical trials: ABPA, open to volunteers
Allergic Bronchopulmonary Aspergillosis
Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis
To understand the current diagnosis and treatment status of ABPA patients, observe their clinical characteristics, prognosis, and treatment outcomes, and identify the relevant factors for poor prognosis in patients.
- Trial name
- NCT06645210
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University Third Hospital
ABPA, Allergic Bronchopulmonary Aspergillosis
Fungal Status and Prognosis in ABPA
This multicenter bidirectional cohort study aims to investigate the clinical characteristics and prognostic outcomes of patients with allergic bronchopulmonary aspergillosis (ABPA) stratified by fungal microbiological status in…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Colonization
- Trial name
- ABPAFUNGAL (NCT07690345)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Environmental Exposure, Asthma
Effects of Environmental Fungal Exposure on Bronchial Asthma, ABPA and Bronchiectasis
This study is a prospective, observational study of patients aged 18-80 years with clinical diagnosis of bronchial asthma, allergic bronchopulmonary aspergillosis (ABPA), bronchiectasis and healthy subjects.
- Conditions
- Environmental Exposure, Asthma, Bronchiectasis, ABPA
- Trial name
- NCT07313904
- Where
- China
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
Allergic Bronchopulmonary Aspergillosis (ABPA)
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and…
- Trial name
- NCT07040332
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD)
Immune Status and Disease Control of Inflammatory Airway Diseases
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked…
- Conditions
- Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
- Trial name
- ISDC-IAD (NCT07493629)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
ABPA, Allergic Bronchopulmonary Aspergillosis
ML-Based ABPA Recurrence Prediction and Clinical Utility
This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Acute Exacerbation
- Trial name
- ABPA-ML (NCT07714863)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning
Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.
- Conditions
- Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning, Multi-omics, Multicenter Study
- Trial name
- NCT07611838
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qianfoshan Hospital
ABPA, Biologics
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA
To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.
- Conditions
- ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA), Cohort Study
- Trial name
- NCT07362693
- Testing
- Biologic Agent
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07530770
- Testing
- Fasenra
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
The investigators hypothesize that a combination of prednisolone and itraconazole would significantly reduce the exacerbation rate at one-year of patients with acute allergic bronchopulmonary aspergillosis (ABPA) compared to…
- Trial name
- PICA (NCT06174922)
- Testing
- Prednisolone, Itraconazole
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities.
- Trial name
- GLITZ (NCT05444946)
- Testing
- Prednisone tablet and Itraconazole, Oral itraconazole
- Where
- 2 sites in India
- Volunteers
- 104 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
ABPA, Allergic Bronchopulmonary Aspergillosis
A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Airway Clearance
- Trial name
- NCT07362667
- Testing
- The patients were treated with bronchoscopic airway clearance and amphotericin B spraying
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Tezepelumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07757841
- Testing
- Tezepelumab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Asthma, COPD (Chronic Obstructive Pulmonary Disease)
T2AIR: Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation in Asthma and COPD
This prospective, real-world observational study (T2AIR Study) evaluates the long-term efficacy and safety of six biologics targeting Type 2 inflammation - omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab, and…
- Trial name
- T2AIR (NCT07823842)
- Testing
- Biologics targeting Type 2 inflammation, Patients with asthma and copd who received standard of care
- Where
- China
- Volunteers
- 538 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China